GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of small win: dual agonist stopped being a problem at week 41 — 19 comments in the full submission. View in context.
602
c/tirzepatide·submitted 3 months ago by u/zeynep_zielinski

small win: dual agonist stopped being a problem at week 41

Labbranch of 8 comments

Been lurking in c/compounding for about 7 months and finally have something worth posting. Short version: week 39, 15mg, and GIP is the bit I still cannot get a straight answer on. I have read the wiki, I have read the last 23 threads, and the answers split roughly down the middle. What I actually want to know is…

Read the full submission and all 19 comments →

This branch

8 comments, started 3 months ago
u/vito_chowdhury58 points·3 months ago·edited

How long at each step before you escalated?

replysharereportpermalink
u/ingrid_correia44 points·3 months ago

How long at each step before you escalated?

Disagree on that part. 98.1% and 98.3% on the same vial is normal.

replysharereportpermalink
u/forest_plot_fionastats10 points·3 months ago

week 18 on Mounjaro and the appetite profile is genuinely different from sema

replysharereportpermalink
u/throwaway_titration35 points·3 months ago

the 15mg is the top of the pen, not the required dose

replysharereportpermalink
u/aurel_lindqvist83 points·3 months ago

Is that on Mounjaro pens or research tirzepatide?

replysharereportpermalink
u/elin_varga24 points·3 months ago

the appetite change on tirz is more than just reduced hunger, it is different machinery

replysharereportpermalink
u/santiago_villalobos67 points·3 months ago·edited

the dual agonism hits different and that is why people describe it differently

replysharereportpermalink
[deleted]29 points·3 months ago

[deleted]

replysharereportpermalink

← back to the whole thread

About c/tirzepatide

Tirzepatide-specific discussion: the dual-agonist pharmacology, the 2.5 → 15mg ladder, the appetite profile people describe as different from semaglutide, and the SURMOUNT/SURPASS trial programme. Comparisons with semaglutide are welcome as long as they are specific about dose equivalence being unknown.

187kmembers
130submissions
Aug 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/tirzepatide
c/tirzepatide rules
  1. "Tirz is better than sema" needs a comparator dose or it is a vibe, not a claim.
  2. Vial-splitting and self-compounding discussion stays in c/reconstitution.
  3. No pen-cracking tutorials. Discussing that people do it is fine; instructions are not.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/titration_marshalu/incretin_ivyu/quiet_moderatoru/dexa_twice_yearly
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →